CHENGDU HUASUN TECHNOLOGY GROUP INC. , LTD. Chengdu huasun technology group Inc. , LTD. Share Price
Equities
000790
CNE0000001H5
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.24 CNY | +10.13% |
|
+14.91% | -16.21% |
| 05-03 | Huasun Technology to Cancel 3.8 Million Repurchased Shares | MT |
| 04-29 | Chengdu huasun technology group Inc. , LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2022 | 873M 121M 9.62B | Sales 2023 | 1B 139M 11.05B | Capitalization | 3.18B 439M 34.99B |
|---|---|---|---|---|---|
| Net income 2022 | 41M 5.66M 452M | Net income 2023 | 27M 3.73M 297M | EV / Sales 2022 | 3.33 x |
| Net Debt 2022 | 46.1M 6.37M 508M | Net Debt 2023 | 204M 28.2M 2.25B | EV / Sales 2023 | 3.37 x |
| P/E ratio 2022 |
65
x | P/E ratio 2023 |
127
x | Employees | - |
| Yield 2022 |
0.22% | Yield 2023 |
-
| Free-Float | 73.04% |
More Fundamentals
* Assessed data
More news
| 1 day | +10.13% | ||
| 1 week | +14.91% | ||
| 1 month | -4.72% | ||
| 3 months | +14.91% | ||
| 6 months | -21.48% | ||
| Current year | -16.21% |
1 week
3.68
4.24
1 month
3.354.24
Current year
3.025.33
1 year
3.025.87
3 years
3.027.86
5 years
3.027.86
10 years
3.0217.03
| Managers | Title | Age | Since |
|---|---|---|---|
Jun Li
DFI | Director of Finance/CFO | 44 | - |
Ming Liang Huang
CHM | Chairman | 56 | - |
Duo Xue Wang
BRD | Director/Board Member | 40 | 29/03/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiao Ling Xin
BRD | Director/Board Member | 46 | 31/05/96 |
Hai Lan
BRD | Director/Board Member | 53 | 23/06/21 |
Ming Liang Huang
CHM | Chairman | 56 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.67% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/04/24 | 4.24 | +10.13% | 44,406,370 |
| 29/04/24 | 3.85 | +3.77% | 9,337,694 |
| 26/04/24 | 3.71 | +0.54% | 5,771,634 |
| 25/04/24 | 3.69 | +1.37% | 7,873,674 |
End-of-day quote Shenzhen S.E., April 29, 2024
More quotes
Chengdu Huasun Technology Group Co Ltd, formerly Chengdu Taihe Health Technology Group Inc., Ltd., is principally engaged in manufacture and distribution of Chinese medicines and Western medicines, fabrication and installation services of steel structures, as well as production and sale of bio-engineering products. The Company primarily provides Chinese medicines, Western medicines, biological drugs, veterinary drugs and veterinary biological vaccines, as well as modern steel structures. Its pharmaceutical products include oral liquid, capsules, biological products and veterinary drugs, among others. The Company operates its businesses primarily in the China domestic market, with Sichuan province as its main market.
Sector
Pharmaceuticals
Calendar
29/05/2024
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -16.21% | 368M | |
| +26.08% | 681B | |
| +21.85% | 556B | |
| -4.77% | 361B | |
| +16.97% | 325B | |
| +5.69% | 285B | |
| +13.68% | 235B | |
| +3.65% | 199B | |
| -11.12% | 189B | |
| -3.40% | 157B |
- Stock Market
- Equities
- 000790 Stock
